On the one hand, AD patients with plasma ACE2 levels may have increased risk of COVID‐19 infection, hospitalization, and mortality, and assessment of plasma ACE2 levels may be a means of identifying AD patients at high risk for adverse COVID‐19 outcomes. Here, ACE2 is linked to COVID-19.